vimarsana.com
Home
Live Updates
Kymera Therapeutics Doses First Patient in Phase 1 Oncology
Kymera Therapeutics Doses First Patient in Phase 1 Oncology
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of... | May 19, 2023
Related Keywords
Watertown ,
Massachusetts ,
United States ,
Boston ,
Bruce Jacobs ,
Todd Cooper ,
Chris Brinzey ,
Jared Gollob ,
Exchange Commission ,
Corporate Affairs ,
Boston Globe ,
Kymera Therapeutics Inc ,
Nasdaq ,
Chief Medical Officer ,
Fierce Biotech ,
Boston Business Journal ,
Private Securities Litigation Reform Act ,
Kymera Therapeutics ,
Kymera Therapeutic ,
Quarterly Report ,
Financial Officer ,
Vice President ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Us ,
Ighly ,
Kpotent ,
End ,
Elective ,
Eterobifunctional ,
Egrader ,
F ,
The ,
Ddm2 ,
Ncoprotein ,
Ith ,
Differentiated ,
Profile ,
Rom ,
Mall ,
Olecule ,
Inhibitors ,
N ,
Development ,
Or ,
Reatment Kymr Us5015751044 ,